Starpharma (ASX:SPL) share price lifts on supply and distribution deal

The company’s shares are rebounding from yesterday’s 52-week low.

| More on:
Two Archer Materials lab assistants wearing white coats discuss results they see on a computer screen

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher today following an update from the biopharmaceutical company.

At the time of writing, the dendrimer products developer’s shares are up 3.70% to $1.12.

What did Starpharma announce?

According to its release, Starpharma announced it has signed an initial supply contract for Viraleze in Vietnam.

Viraleze is an antiviral nasal spray that has been shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses. This includes multiple variants of SARS-CoV-2 (COVID-19), influenza, RSV, SARS, and MERS (Middle East Respiratory Syndrome).

The first orders of around 100,000 units of Viraleze are expected to arrive in Vietnam sometime in early November. Launch preparations for the product are anticipated to commence shortly. A portion of these orders will also be donated to hospitals and other healthcare organisations across the country.

Vietnam with a population of about 97 million, is currently experiencing a significant Delta outbreak despite 20% of its population being fully vaccinated. According to the World Health Organisation (WHO), the COVID-19 has taken 21,000 lives in Vietnam so far.

Starpharma noted that registration for the product is well advanced in the south-east Asian country. Once completed, an ongoing distribution agreement is expected to follow involving much larger orders of Viraleze. These arrangements are exclusive for retail, pharmacies, clinics, and hospitals in Vietnam.

Starpharma CEO, Dr Jackie Fairley commented:

We are very pleased to be able to make Viraleze available to Vietnamese consumers and frontline workers next month, especially given the current Delta outbreak and vaccination rates in Vietnam. This supply contract is one of a number of international commercial arrangements for Viraleze being negotiated by Starpharma and we look forward to making further announcements about those soon.

Starpharma share price snapshot

At the start of 2021, Starpharma shares rocketed to an all-time high of $2.52 in mid-February. However, the sharp rise quickly came, and then its shares crashed down the following month.

Since then, the company’s shares have continued their downward trend, hitting a 52-week low of $1.04 just yesterday.

Starpharma is down by more than 20% in the past 12 months, and almost 30% lower in 2021.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.
Healthcare Shares

Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

Read more »

A sad looking scientist sitting and upset about a share price fall.
Earnings Results

Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

Read more »

A man waking up happy with a smile on his face and arms outstretched representing the hefty Adairs dividend yield
Earnings Results

ResMed share price on watch following solid FY22 growth

ResMed has released its full year results...

Read more »

Female doctor with a mask holds out hand in a stop gesture.
Capital Raising

Up 90% in 2 weeks, here’s why the Paradigm share price has been halted

The biopharmaceutical company is planning a capital raise.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Broker Notes

Goldman Sachs gives its verdict on the CSL share price

Where next for CSL's shares?

Read more »

Healthcare Shares

Mayne Pharma share price rockets 25% on $680 million payday

It's been a good day for the ASX pharmaceutical company.

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

What’s with the Polynovo share price on Wednesday?

Shares in the ASX medical devices company hit their year to date high today before retreating again.

Read more »

A man in a wheelchair stretches both arms into the air in success.
Healthcare Shares

Imugene share price lifts 11% on clinical trial update

Imugene shares are flying higher today.

Read more »